HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation
Broad scientific visibility across multiple programs, disease areas, and immune contexts reflects sustained execution and expanding external recognition in 2026
[Taipei, Shanghai, San Francisco | April 20, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.
Through H1 2026, HanchorBio has delivered or secured a diverse set of scientific presentations spanning its lead clinical and translational programs, including HCB101 monotherapy, HCB101 combination therapy, HCB301, and HCB206. These presentations reflect the Company’s continued progress in building clinical and translational evidence for its proprietary FBDB™ platform and its strategy to develop differentiated immune backbones and multifunctional biologics across oncology and autoimmune diseases.
“Strong and sustained scientific visibility matters because it reflects both execution and relevance,” said Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (U.S.A.) of HanchorBio. “Our H1 2026 conference activity demonstrates that HanchorBio is continuing to generate and communicate meaningful clinical and translational data across multiple programs, disease areas, and presentation formats. Importantly, we are not only reporting continued progress in oncology, but also extending visibility across broader autoimmune indications.”
During Q1 2026, HanchorBio delivered a strong series of presentations across key international meetings, including ESMO-TAT, ESTRO/ICHNO, ASCO-GI, AACR-IO, APGCC, and TSITC. In total, the Company delivered 10 presentations in Q1 2026, including 4 oral presentations, 5 posters, and 1 symposium presentation.
Following a strong Q1 2026 conference season, HanchorBio is continuing to build scientific visibility in Q2 2026 through participation in 7 conferences, representing 11 abstracts, 1 symposium presentation, and 1 keynote speaker invitation across multiple programs and disease areas. Confirmed Q2 activities to date include presentations at GBCC, TJCC, the ASCO Annual Meeting, and FOCiS, while submissions to EMSO-TAT Asia, ASCO Breakthrough, and JCA-AACR remain under review. These submissions span multiple areas, including gastric cancer, colorectal cancer, head and neck cancer, TNBC, and immuno-oncology-focused translational work, as well as autoimmune-related studies. The FOCiS late-breaking abstract, in particular, highlights the clinical and translational validation of selective CD47-SIRPα engineering across both oncology and autoimmunity, including HCB206 data in an SLE patient-derived PBMC-engrafted humanized model.
H1 2026 Scientific Communications Highlights
- 10 presentations delivered in Q1 2026
- 5 presentations accepted or scheduled and 7 abstracts pending in Q2 2026
- 4 programs represented: HCB101 monotherapy, HCB101 combination therapy, HCB301, and HCB206
- Scientific visibility expanded beyond oncology into autoimmune and broader immune-related biology
The Company’s 2026 scientific communications are intended to reinforce the evolving clinical and translational potential of HanchorBio’s pipeline, and to highlight the product-enabling capabilities of its proprietary FBDB™ technology platform.
“HanchorBio’s conference activity in 2026 reflects a disciplined scientific communications strategy aligned with the progress of our pipeline,” said Scott Liu, PhD, Founder, Chairman, and Chief Executive Officer of HanchorBio. “We believe continued visibility at major medical meetings is important not only for scientific exchange, but also for demonstrating the breadth, consistency, and growing maturity of our development programs. We are pleased to see this momentum continuing into Q2 and potentially through the second half of the year.”
About HCB101
HCB101 is an AI-guided (AlphaFold) structurally engineered SIRPα-IgG4 Fc fusion protein designed to selectively target the CD47-SIRPα innate immune checkpoint while reducing hematologic toxicity associated with earlier CD47-targeting therapies. The program is being developed as a differentiated innate immune backbone with broad combination potential across multiple tumor types and therapeutic settings.
About HCB301
HCB301 is a tri-specific fusion protein designed to integrate modulation of the CD47/SIRPα, PD-1/PD-L1, and TGFβ/ TGFβ-R pathways within a single molecule. By simultaneously addressing multiple interdependent mechanisms of immune resistance, the program reflects HanchorBio’s broader strategy to develop multifunctional biologics with the potential to deliver more coordinated and clinically meaningful immune modulation.
About HCB206
HCB206 is designed to extend HanchorBio’s selective CD47-SIRPα engineering approach beyond oncology into the field of autoimmune disease. By combining targeted B-cell depletion with an engineered innate immune mechanism intended to minimize unwanted hematologic effects, HCB206 reflects the broader versatility of HanchorBio’s platform across diverse immune-mediated disease settings.
About HanchorBio
HanchorBio (TPEx: 7827) is a global clinical-stage biotechnology company focused on developing next-generation immunotherapies for oncology and autoimmune diseases. With operations in Taipei, Shanghai, and San Francisco, the Company is advancing a portfolio of differentiated biologics enabled by its proprietary FBDB™ (Fc-Based Designer Biologics) platform. HanchorBio’s pipeline is designed to address complex disease biology through rationally engineered molecules with the potential to activate both innate and adaptive immune pathways.